Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study
Authors:
- 16 August 2013
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 2 (4) , 298-309
Abstract
This double‐blind, randomized, placebo‐ and positive‐controlled, parallel‐group study evaluated the effect of vortioxetine (Lu AA21004), an investigational multimodal antidepressant, on QT interval in accordance with current guidelines of the International Conference on Harmonisation (ICH‐E14). A total of 340 healthy men were randomized to receive 1 of 4 treatments for 14 days: (1) vortioxetine 10 mg once daily (QD), (2) vortioxetine 40 mg QD, (3) placebo QD, or (4) placebo QD on Days 1 through 13 followed by a single dose of moxifloxacin 400 mg (positive control). The primary endpoint was the largest time‐matched, baseline‐adjusted least‐squares (LS) mean difference for the individual‐corrected QT interval (QTcNi [linear]) between vortioxetine and placebo. Alternative QT correction formulas (i.e., Fredericia [QTcF], Bazett [QTcB], Framingham [QTcFm], and QTcNi [nonlinear]) were used as secondary endpoints. The upper bound of the 2‐sided 90% confidence interval around the LS mean difference from placebo for baseline‐adjusted QTcNi (linear), QTcF, QTcB, QTcFm, and QTcNi (nonlinear) did not exceed 10 ms at any time point after multiple doses of vortioxetine 10 mg (therapeutic) or 40 mg (supratherapeutic). Overall, the study results indicate that vortioxetine is unlikely to affect cardiac repolarization in healthy subjects.Keywords
This publication has 16 references indexed in Scilit:
- Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT StudiesThe Journal of Clinical Pharmacology, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentBritish Journal of Pharmacology, 2010
- The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidanceBritish Journal of Pharmacology, 2010
- Mechanisms of Drug Induced QT Interval ProlongationCurrent Drug Safety, 2010
- Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspectiveBritish Journal of Pharmacology, 2008
- Concentration‐QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory ReviewThe Journal of Clinical Pharmacology, 2008
- Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic applicationPharmacology & Therapeutics, 2006
- The significance of QT interval in drug developmentBritish Journal of Clinical Pharmacology, 2002
- Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjectsClinical Pharmacology & Therapeutics, 2000